Trypanosoma cruzi and Chagas disease: diversity, progress and challenges

Miles, Michael A.

doi:10.1590/0074-02760210193chgsb

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is prevalent in Latin American rural communities. Chagas disease consequences are a leading cause of cardiac mortality and disability in that part of the world, as well as impairment from both heart and gastrointestinal illness [ 8 ]. In the first stage of the disease, high levels of parasitemia and atypical symptoms of infection are present.…”

Section: Introductionmentioning

confidence: 99%

Core Proteomics and Immunoinformatic Approaches to Design a Multiepitope Reverse Vaccine Candidate against Chagas Disease

Islam

Sanjida²,

Ahmed

et al. 2022

Vaccines

View full text Add to dashboard Cite

Chagas disease is a tropical ailment indigenous to South America and caused by the protozoan parasite Trypanosoma cruzi, which has serious health consequences globally. Insect vectors transmit the parasite and, due to the lack of vaccine availability and limited treatment options, we implemented an integrated core proteomics analysis to design a reverse vaccine candidate based on immune epitopes for disease control. Firstly, T. cruzi core proteomics was used to identify immunodominant epitopes. Therefore, we designed the vaccine sequence to be non-allergic, antigenic, immunogenic, and to have better solubility. After predicting the tertiary structure, docking and molecular dynamics simulation (MDS) were performed with TLR4, MHC-I, and MHC-II receptors to discover the binding affinities. The final vaccine design demonstrated significant hydrogen bond interactions upon docking with TLR4, MHC-I, and MHC-II receptors. This indicated the efficacy of the vaccine candidate. A server-based immune simulation approach was generated to predict the efficacy. Significant structural compactness and binding stability were found based on MDS. Finally, by optimizing codons on Escherichia coli K12, a high GC content and CAI value were obtained, which were then incorporated into the cloning vector pET2+ (a). Thus, the developed vaccine sequence may be a viable therapy option for Chagas disease.

show abstract

Section: Introductionmentioning

confidence: 99%